Canton Hathaway LLC Sells 150 Shares of Danaher Co. (NYSE:DHR)

Canton Hathaway LLC decreased its position in Danaher Co. (NYSE:DHR) by 1.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,575 shares of the conglomerate’s stock after selling 150 shares during the quarter. Danaher makes up 0.7% of Canton Hathaway LLC’s portfolio, making the stock its 24th biggest holding. Canton Hathaway LLC’s holdings in Danaher were worth $2,657,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of DHR. AMF Tjanstepension AB purchased a new position in shares of Danaher during the 3rd quarter valued at $5,923,000. Howard Capital Management Group LLC lifted its position in Danaher by 4.1% during the third quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 48 shares during the last quarter. Allworth Financial LP grew its stake in shares of Danaher by 6.1% in the 3rd quarter. Allworth Financial LP now owns 5,337 shares of the conglomerate’s stock worth $1,484,000 after buying an additional 307 shares in the last quarter. Arkadios Wealth Advisors raised its position in shares of Danaher by 1.8% during the 3rd quarter. Arkadios Wealth Advisors now owns 3,572 shares of the conglomerate’s stock valued at $993,000 after buying an additional 64 shares in the last quarter. Finally, First Financial Bankshares Inc grew its position in Danaher by 0.5% in the third quarter. First Financial Bankshares Inc now owns 42,759 shares of the conglomerate’s stock worth $11,888,000 after acquiring an additional 226 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Trading Up 0.5 %

Shares of NYSE:DHR opened at $211.23 on Tuesday. The business’s 50-day moving average is $226.25 and its 200 day moving average is $246.44. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. Danaher Co. has a 1 year low of $196.80 and a 1 year high of $281.70. The firm has a market capitalization of $150.97 billion, a P/E ratio of 40.01, a P/E/G ratio of 2.66 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period last year, the company posted $2.09 earnings per share. On average, research analysts predict that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.32 dividend. This is a positive change from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a yield of 0.61%. Danaher’s dividend payout ratio (DPR) is 24.24%.

Insider Buying and Selling at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. The Goldman Sachs Group set a $250.00 price objective on Danaher in a research report on Wednesday, January 15th. Citigroup decreased their price target on Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Wells Fargo & Company cut their price objective on Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Royal Bank of Canada reiterated an “outperform” rating and set a $277.00 target price (down from $299.00) on shares of Danaher in a research report on Thursday, January 30th. Finally, Raymond James reaffirmed a “market perform” rating on shares of Danaher in a research note on Monday, February 3rd. Seven equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average target price of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.